FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563145412> ?p ?o ?g. }

• W2563145412 endingPage "952" @default.
• W2563145412 startingPage "943" @default.
• W2563145412 abstract "Objective To assess the effects of baricitinib on lipid profiles in patients with moderate‐to‐severe rheumatoid arthritis. Methods Treatment with once‐daily doses of baricitinib (1, 2, 4, or 8 mg) or placebo was studied in 301 randomized patients. Changes in lipid profile and lipoprotein particle size and particle number were assessed at weeks 12 and 24, and associations with clinical efficacy were evaluated. Apolipoproteins were assessed at weeks 4 and 12 in the placebo group and the 4‐mg and 8‐mg baricitinib groups. Results Treatment with baricitinib resulted in dose‐dependent increases in serum lipid levels from baseline to week 12 (low‐density lipoprotein [LDL] cholesterol increases of 3.4 mg/dl and 11.8 mg/dl in the 1 mg and 8 mg treatment groups, respectively; high‐density lipoprotein [HDL] cholesterol increases of 3.3 mg/dl and 8.1 mg/dl, respectively; triglycerides increases of 6.4 mg/dl and 15.4 mg/dl, respectively). Group‐wise mean increases in LDL cholesterol were coincident with mean increases in large LDL particles and mean reductions in small dense LDL particles. Increases from baseline to week 12 in apolipoprotein A‐I, apolipoprotein B, and apolipoprotein CIII were observed with 4‐mg doses of baricitinib (9.5%, 6.8%, and 23.0%, respectively) and with 8‐mg doses (12.2%, 7.1%, and 19.7%, respectively), with no increase in LDL‐associated apolipoprotein CIII (–4.5% with 4‐mg baricitinib; –9.0% with 8‐mg baricitinib). Baricitinib reduced HDL‐associated serum amyloid A when administered at 4 mg (−36.0%) and 8 mg (−32.0%); a significant reduction in lipoprotein (a) was observed only with 8‐mg doses (−16.6%). Increased HDL cholesterol at week 12 correlated with improved Disease Activity Scores and Simplified Disease Activity Index; changes in total cholesterol, LDL cholesterol, and triglycerides did not reveal a similar relationship. Conclusion Baricitinib‐associated increases in serum lipid levels were observed in this study. Increases in levels of HDL cholesterol correlated with improved clinical outcomes." @default.
• W2563145412 created "2017-01-06" @default.
• W2563145412 creator A5003819213 @default.
• W2563145412 creator A5014147030 @default.
• W2563145412 creator A5017598610 @default.
• W2563145412 creator A5019567028 @default.
• W2563145412 creator A5032467182 @default.
• W2563145412 creator A5032492386 @default.
• W2563145412 creator A5049261212 @default.
• W2563145412 creator A5055441251 @default.
• W2563145412 creator A5071119246 @default.
• W2563145412 creator A5078824497 @default.
• W2563145412 creator A5080646462 @default.
• W2563145412 date "2017-04-26" @default.
• W2563145412 modified "2023-09-30" @default.
• W2563145412 title "Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis" @default.
• W2563145412 cites W1515206644 @default.
• W2563145412 cites W1572054273 @default.
• W2563145412 cites W1588610010 @default.
• W2563145412 cites W1597643670 @default.
• W2563145412 cites W1984875752 @default.
• W2563145412 cites W2026387613 @default.
• W2563145412 cites W2062697678 @default.
• W2563145412 cites W2063485775 @default.
• W2563145412 cites W2066568926 @default.
• W2563145412 cites W2077550414 @default.
• W2563145412 cites W2096809109 @default.
• W2563145412 cites W2102941237 @default.
• W2563145412 cites W2110177517 @default.
• W2563145412 cites W2115144341 @default.
• W2563145412 cites W2117622925 @default.
• W2563145412 cites W2123414080 @default.
• W2563145412 cites W2126736180 @default.
• W2563145412 cites W2131666890 @default.
• W2563145412 cites W2143835145 @default.
• W2563145412 cites W2149026148 @default.
• W2563145412 cites W2156166356 @default.
• W2563145412 cites W2159106700 @default.
• W2563145412 cites W2163087340 @default.
• W2563145412 cites W2170973130 @default.
• W2563145412 cites W2530844910 @default.
• W2563145412 doi "https://doi.org/10.1002/art.40036" @default.
• W2563145412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28029752" @default.
• W2563145412 hasPublicationYear "2017" @default.
• W2563145412 type Work @default.
• W2563145412 sameAs 2563145412 @default.
• W2563145412 citedByCount "40" @default.
• W2563145412 countsByYear W25631454122017 @default.
• W2563145412 countsByYear W25631454122018 @default.
• W2563145412 countsByYear W25631454122019 @default.
• W2563145412 countsByYear W25631454122020 @default.
• W2563145412 countsByYear W25631454122021 @default.
• W2563145412 countsByYear W25631454122022 @default.
• W2563145412 countsByYear W25631454122023 @default.
• W2563145412 crossrefType "journal-article" @default.
• W2563145412 hasAuthorship W2563145412A5003819213 @default.
• W2563145412 hasAuthorship W2563145412A5014147030 @default.
• W2563145412 hasAuthorship W2563145412A5017598610 @default.
• W2563145412 hasAuthorship W2563145412A5019567028 @default.
• W2563145412 hasAuthorship W2563145412A5032467182 @default.
• W2563145412 hasAuthorship W2563145412A5032492386 @default.
• W2563145412 hasAuthorship W2563145412A5049261212 @default.
• W2563145412 hasAuthorship W2563145412A5055441251 @default.
• W2563145412 hasAuthorship W2563145412A5071119246 @default.
• W2563145412 hasAuthorship W2563145412A5078824497 @default.
• W2563145412 hasAuthorship W2563145412A5080646462 @default.
• W2563145412 hasBestOaLocation W25631454121 @default.
• W2563145412 hasConcept C126322002 @default.
• W2563145412 hasConcept C134018914 @default.
• W2563145412 hasConcept C142724271 @default.
• W2563145412 hasConcept C185592680 @default.
• W2563145412 hasConcept C204787440 @default.
• W2563145412 hasConcept C27081682 @default.
• W2563145412 hasConcept C2776104379 @default.
• W2563145412 hasConcept C2777077863 @default.
• W2563145412 hasConcept C2777575956 @default.
• W2563145412 hasConcept C2778163477 @default.
• W2563145412 hasConcept C2778270857 @default.
• W2563145412 hasConcept C2780072125 @default.
• W2563145412 hasConcept C2780745583 @default.
• W2563145412 hasConcept C62746215 @default.
• W2563145412 hasConcept C71924100 @default.
• W2563145412 hasConceptScore W2563145412C126322002 @default.
• W2563145412 hasConceptScore W2563145412C134018914 @default.
• W2563145412 hasConceptScore W2563145412C142724271 @default.
• W2563145412 hasConceptScore W2563145412C185592680 @default.
• W2563145412 hasConceptScore W2563145412C204787440 @default.
• W2563145412 hasConceptScore W2563145412C27081682 @default.
• W2563145412 hasConceptScore W2563145412C2776104379 @default.
• W2563145412 hasConceptScore W2563145412C2777077863 @default.
• W2563145412 hasConceptScore W2563145412C2777575956 @default.
• W2563145412 hasConceptScore W2563145412C2778163477 @default.
• W2563145412 hasConceptScore W2563145412C2778270857 @default.
• W2563145412 hasConceptScore W2563145412C2780072125 @default.
• W2563145412 hasConceptScore W2563145412C2780745583 @default.
• W2563145412 hasConceptScore W2563145412C62746215 @default.
• W2563145412 hasConceptScore W2563145412C71924100 @default.
• W2563145412 hasFunder F4320307758 @default.

• next